What is the current market size and future outlook for the turner syndrome market?
The turner syndrome market size has grown strongly in recent years. It will grow from $2.36 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increasing awareness of the women health, rising healthcare expenditure, growing healthcare sector, increasing awareness and early diagnosis of turner syndrome, and public awareness initiatives.
The turner syndrome market size is expected to see strong growth in the next few years. It will grow to $3.42 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising cases of structural abnormalities of the x chromosome, widespread adoption of estrogen replacement therapy, increasing utilization of chromosomal microarray analysis (cma) for disease diagnosis, increasing female population, increasing research and development activities. Major trends in the forecast period include adoption of new technologies, product launches, advances in growth hormone therapy, demand for hormonal treatments, development of novel therapies.
Get Your Free Sample of The Global Turner Syndrome Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21310&type=smp
How has the turner syndrome market evolved, and what factors have shaped its growth?
The increasing female population is expected to propel the growth of the turner syndrome market going forward. The female population refers to the total number of females living in a specific area or worldwide at a given time. The increasing female population is driven by factors such as higher life expectancy, improved healthcare, and demographic shifts. Turner syndrome treatment supports the female population by providing growth hormone therapy to improve stature, estrogen replacement to induce puberty and maintain bone health, and multidisciplinary medical care to manage associated conditions, ultimately enhancing physical development, reproductive health, and overall well-being. For instance, in March 2024, according to the Census Bureau, a US-based government agency, the United States had a female population of approximately 168 million as of July 2022. Additionally, there were about 1.9 million more females age 85 and older. Furthermore, in December 2022, according to the report published by CEIC Data, a UK-based financial service company, the number of females aged 15-64 was reported at 2,951,856 in 2022, reflecting an increase from 2,940,645 in 2021. Therefore, increasing female population is driving the growth of the turner syndrome market.
What are the major segments of the turner syndrome market?
The turner syndrome market covered in this report is segmented –
1) By Type: Classical Turner Syndrome, Mosaic Turner syndrome
2) By Therapy Type: Growth Hormone Therapy, Estrogen And Progesteron, Replacement Therapy, Other Therapy Types
3) By Drug Type: Norditropin, Oxandrolone, Humatrope, Somatropin, Oxandrin, Genotropin, Nutropin, Zomacton
4) By End-User: Hospitals, Homecare, Specialty Clinics, Surgical Centres, Other End-Users
Subsegments:
1) By Classical Turner Syndrome: Complete Monosomy X, X Chromosome Deletion
2) By Mosaic Turner Syndrome: Mosaicism With 45,X/46,XX Karyotype, Mosaicism With 45,X/46,XY Karyotype
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/turner-syndrome-global-market-report
Which companies dominate the turner syndrome market?
Major companies operating in the turner syndrome market are Pfizer Inc., Sanofi SA, AstraZeneca Plc, Abbott Laboratories, Novartis AG, LG Chem Ltd., Eli Lilly and Company, Novo Nordisk, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Pharma, Ferring Pharmaceutical, BioMarin Pharmaceutical Inc., United Imaging Healthcare Co. Ltd., Daewoong Pharmaceutical Co. Ltd., OPKO Health Inc., Hanmi Pharmaceutical Co. Ltd., Dong-A ST Co. Ltd., GeneScience Pharmaceuticals Co. Ltd., Ascendis Pharma, AnkeBio Co. Ltd., Biopartners Inc., Kexing Biopharm Co. Ltd.
How will evolving trends contribute to the growth of the turner syndrome market?
Major companies operating in the turner syndrome market are focusing on the clinical trials for developing innovative products, such as pediatric growth hormone medications, to effectively stimulate growth, improve height outcomes, and support overall development in children with growth hormone deficiencies or growth-related disorders. Pediatric growth hormone medications are synthetic or recombinant hormone treatments used to stimulate growth and development in children with growth hormone deficiency (GHD) or other medical conditions affecting height and growth. For instance, in December 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company announced positive results from the Phase 2 New InsiGHTS trial of TransCon hGH (lonapegsomatropin) in children with Turner syndrome. The trial included 49 prepubertal children aged 1-10 years with Turner syndrome. TransCon hGH demonstrated improved growth across all three starting dose cohorts, matching the performance of daily somatropin. The trial results support the potential market expansion of TransCon hGH into Turner syndrome, with a comparable safety profile and efficacy to daily treatment.
What are the key regional dynamics of the turner syndrome market, and which region leads in market share?
North America was the largest region in the turner syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the turner syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Turner Syndrome Market Report 2025 Offer?
The turner syndrome market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Turner syndrome is a genetic condition that affects females and results from the partial or complete absence of one X chromosome. This condition can lead to a range of developmental and medical challenges, including short stature, delayed puberty, infertility, heart defects, and certain learning difficulties. Turner syndrome is typically diagnosed through karyotype testing and managed with treatments such as specialized medical care to address associated health concerns.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21310
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
